|
Physiomics PLC - Abingdon, Oxfordshire-based mathematical modelling and data science for new medicines - Says it has been awarded a significant contract by a new UK-based biotech client, which it left unnamed. ‘This client sits at the forefront of AI-driven design and development of novel therapies across various therapeutic areas,’ the company says. The project involves the use of Physiomics’ Virtual Tumour technology to help guide the phase 1b/2 dosing regimens for one of their oncology assets and benchmark it against the competition. The project is valued at £161,580 and is anticipated to be completed over the next five months. Chief Executive Peter Sargent comments: ‘We at Physiomics are very excited about starting our first project with this exciting new client and we look forward to working with their team over the coming months and hopefully on further programmes in the future.’ Current stock price: 1.31 pence each, up 0.8% in London on Friday afternoon 12-month change: down 35% Copyright 2024 Alliance News Ltd. All Rights Reserved.
|
